abiraterone has been researched along with Diabetes Mellitus in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bennett, CL; Carson, KR; Drake, BF; Eisen, SA; Knoche, EM; Luo, S; Reimers, MA; Sanfilippo, KM; Schoen, MW; Whitmer, AL; Yan, Y | 1 |
| Schmidt, C | 1 |
2 other study(ies) available for abiraterone and Diabetes Mellitus
| Article | Year |
|---|---|
Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases.
Topics: Abiraterone Acetate; Cardiovascular Diseases; Diabetes Mellitus; Humans; Male; Nitriles; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome; Veterans | 2023 |
Abiraterone and MVD3100 take androgen deprivation to a new level.
Topics: Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Diabetes Mellitus; Dihydrotestosterone; Drug Approval; Gonadotropin-Releasing Hormone; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Testosterone; Time Factors; United States; United States Food and Drug Administration | 2011 |